病毒学
重组DNA
整合酶
埃法维伦兹
桑格测序
抗药性
逆转录酶
生物
重组病毒
聚合酶链反应
利比韦林
基因组
遗传学
突变
病毒
人类免疫缺陷病毒(HIV)
基因
病毒载量
抗逆转录病毒疗法
作者
Yun Lan,Linghua Li,Xizi Deng,Xiaoli Cai,Junbin Li,Qinghong Fan,Liya Li,Weiping Cai,Chunliang Lei,Fengyu Hu
标识
DOI:10.1089/aid.2020.0278
摘要
The wide variety of new HIV-1 recombinant variants are a predominant challenge for understanding the molecular epidemiology and preventing the spread of the HIV-1 epidemic. In this study, we confirmed a novel HIV-1 unique B/C recombinant (ZLQ01186) isolated from a male patient infected with HIV-1 through injection drug use in Foshan city, Guangdong Province. The near full-length genome was amplified, and then the polymerase chain reaction products were sequenced by Sanger sequencing. The genomic sequence of the strain, with two subtype B segments inserted into the subtype C backbone, was 8,953 bp in length, extending from 647 to 9,599 bp according to the HXB2 genome. In addition, this B/C recombinant strain contained the non-nucleoside reverse transcriptase inhibitor resistance mutation K103N and the integrase strand transfer inhibitor other resistance mutation L74I according to the Stanford University HIV Drug Resistance Database program. The drug resistance profile indicates high-level resistance against efavirenz and rilpivirine. This study identified a recombinant between the main circulating strains, indicating a more complicated trend of the HIV-1 epidemic in Guangdong, China.
科研通智能强力驱动
Strongly Powered by AbleSci AI